From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`Zullow, Keith A <KZullow@goodwinlaw.com>
`Tuesday, June 23, 2020 4:59 PM
`Trials
`SFisher@wc.com; JBerniker@wc.com; BGenderson@wc.com; SMahaffy@wc.com;
`asheh@wc.com; AZolan@wc.com; ebaumgarten@wc.com; mercksitagliptin@wc.com;
`jitty.malik@kattenlaw.com; alissa.pacchioli@kattenlaw.com;
`christopher.west@katten.com; heike.radeke@katten.com; 'Malik, Jitty';
`alissa.pacchioli@katten.com; Van Buskirk, Tedd W.; Teschner, Michael H.; Faegenburg,
`Russell W.; Wong, Jovial; Fundakowski, Claire (CFundakowski@winston.com); Fischer,
`Sarah
`IPR2020-01045 (Teva Pharmaceuticals USA, Inc. et al. v. Merck Sharp & Dohme Corp.,)
`
`To the Honorable Board, 
`
`Pursuant to the Board’s June 18, 2020 Order (IPR2020‐01045, Paper 5), we write to inform the Board that counsel for 
`Mylan, Teva/Watson, DRL and Sun (the petitioners in IPR2020‐00040, IPR2020‐01045, IPR2020‐01060 and IPR2020‐
`01072, respectively) have discussed joinder amongst themselves and with counsel for Merck.  Mylan requested that we 
`inform the Board of the following: 
`
`Mylan will not oppose joining Teva/Watson (IPR2020‐01045), DRL (IPR2020‐01060) and/or Sun (IPR2020‐01072) 
`(collectively “joinder petitioners”) with IPR2020‐00040 so long as each joinder petitioner agrees: (1) to a silent, 
`understudy role throughout the IPR proceedings; (2) that none of the joinder petitioners will seek any change to the 
`current IPR schedule; (3) that none of the joinder petitioners will seek or be permitted additional time to ask questions 
`during any deposition; and (4) any other condition the PTAB sees fit to impose.  Subject to any confidentiality 
`obligations, Mylan does not object to the joinder petitioners attending any deposition.   
`
`Teva/Watson agree to abide by Mylan’s conditions.  Sun and DRL have also indicated that they agree to abide by Mylan’s 
`conditions. 
`
`Merck requested that we inform the Board of the following: 
`
`Patent Owner Merck is considering its position in view of the additional information provided by Petitioner Mylan 
`today.  Merck acknowledges application of the default deadline to oppose the motions for joinder provided in the 
`Board’s June 18, 2020 Order (IPR2020‐01045, Paper 5), and will continue to confer with counsel for Petitioners in 
`advance of that deadline to understand how, if at all, the issues may be narrowed. 
`
`Respectfully, 
`
`Keith A. Zullow 
`Counsel for Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc. 
`
`Keith A. Zullow 
`
`Goodwin Procter LLP
`The New York Times Building
`620 Eighth Avenue
`
`1
`
`IPR2020-01045, -01060, -01072
`Ex. 3002
`
`

`

`New York, NY 10018
`o +1 212 813 8846
`f +1 646 558 4226
`KZullow@goodwinlaw.com | goodwinlaw.com
`
`*******************************************************************
`This message was sent from Goodwin Procter LLP and is intended only for the designated recipient(s). It may
`contain confidential or proprietary information and may be subject to the attorney-client privilege or other
`confidentiality protections. If you are not a designated recipient, you may not review, copy or distribute this
`message. If you receive this in error, please notify the sender by reply e-mail and delete this message. Thank
`you.
`*******************************************************************
`
`2
`
`